Source: Daily Journal
San Diego Intellectual Property partner Robert Bedgood advised Spark Therapeutics Inc. on its patent portfolio diligence in its $4.8 billion sale to pharmaceutical company Roche Holding AG.
The transaction is expected to close in the second quarter of 2019, subject to regulatory approvals and other conditions.
Based in Philadelphia, Spark Therapeutics develops gene therapies. According to Spark Therapeutics CEO Jeffrey Marrazzo, the biotechnology company is the only one to successfully commercialize a gene therapy for a genetic disease in the U.S. These gene therapies seek to treat genetic diseases such as blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. The company has one commercial asset and four programs now in clinical trials.